VRXA compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

VRXAVeraxa Biotech AG - Post de-SPAC

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

VRXAVeraxa Biotech AG - Post de-SPAC

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

VRXA

No earnings history for VRXA.

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

= impliedVRXA realized, solidLLY realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

VRXAVeraxa Biotech AG - Post de-SPAC

0.90▼−5.42%

Mkt cap$13.8MRevenue—Revenue—

LLYELI Lilly & Co

1,364.790.00%

Regular sessionNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Regular sessionNov 6 '26

VRXAVeraxa Biotech AG - Post de-SPAC

LLYELI Lilly & Co

0.90▼−5.42%

Price

1,364.790.00%

$13.8M

Mkt cap

$1.2T

—

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

VRXA0.90▼−5.42%vsLLY1,364.790.00%Regular sessionNov 6 '26